IO Biotech's Phase 3 Trial Results Boost Stock Movement

IO Biotech shares are trading higher after announcing the upcoming disclosure of topline results from a pivotal Phase 3 trial of its cancer vaccine Cylembio in combination with Keytruda for advanced melanoma treatment.